Embrex Names Frederic A. David, D.V.M., Regional Director - Europe, Middle East, Africa.Business Editors/Health & Medical Writers RESEARCH TRIANGLE PARK Research Triangle Park, research, business, medical, and educational complex situated in central North Carolina. It has an area of 6,900 acres (2,795 hectares) and is 8 × 2 mi (13 × 3 km) in size. Named for the triangle formed by Duke Univ. , N.C.--(BW HealthWire)--May 16, 2001 Embrex, Inc. (Nasdaq: EMBX) announced today it has named Dr. Frederic A. David as Regional Director, Europe, Middle East, Africa, where Embrex has Inovoject(R) system operations in approximately 15 countries. Dr. David comes to Embrex from Dolisos Animal Health in Toulouse, France, where he was the General Manager. A native of France, he received his Doctor of Veterinary Medicine veterinary medicine, diagnosis and treatment of diseases of animals. An early interest in animal diseases is found in ancient Greek writings on medicine. Veterinary medicine began to achieve the stature of a science with the organization of the first school in the degree from Liege liege In European feudal society, an unconditional bond between a man and his overlord. Thus, if a tenant held estates from various overlords, his obligations to his liege lord, to whom he had paid “liege homage,” were greater than his obligations to the other University in Belgium. He has subsequently earned a Master of Business Administration degree from the Institute of Management in Lyon, France. After an early career working in Mali and in veterinary practice in France, he has spent the last ten years in the animal health business with Elanco, Solvay, Fort Dodge Animal Health and Dolisos at various times in France, the Netherlands and the United States. He has extensive experience in product management, marketing management and general business management across a wide range of animal health products. "As Embrex continues to expand its business throughout the European, Middle Eastern and African regions," stated David M. Baines, Ph.D., Vice President, Global Sales and Marketing, "Dr. David's broad and relevant experience in the international animal health industry will be a asset to Embrex. We look forward to his future contributions." About Embrex Embrex, Inc. is an international agricultural biotechnology company specializing in the poultry industry. In addition to Forbes's 200 Best Small Companies in America and BusinessWeek's Hot Growth 100, Embrex is also listed on the North Carolina North Carolina, state in the SE United States. It is bordered by the Atlantic Ocean (E), South Carolina and Georgia (S), Tennessee (W), and Virginia (N). Facts and Figures Area, 52,586 sq mi (136,198 sq km). Pop. Technology Fast 50, which honors the fastest growing technology companies. Embrex is focused on developing patented biological, mechanical and pharmaceutical products that improve bird health, help reduce production costs and provide other economic benefits to the poultry industry. The company has developed and commercialized the first in ovo platform delivery system called the Inovoject(R) system, a proprietary, automated injection system which eliminates the need for manual vaccination of newly hatched broiler broiler a young (about 8 weeks old) male or female chicken weighing 3 to 3.5 lb. chicks. Embrex has also developed and markets Bursaplex(R), the first in ovo VNF VNF Voies Navigables de France VNF Virtual Network Feature VNF Very-Near Field (R)-based vaccine for inoculating against infectious bursal disease Infectious Bursal Disease (IBD) is a highly contagious disease of young chickens caused by infectious bursal disease virus (IBDV), characterized by immunosuppression and mortality generally at 3 to 6 weeks of age. (IBD IBD abbr. inflammatory bowel disease Inflammatory bowel disease (IBD) Disease in which the lining of the intestine becomes inflamed. Mentioned in: Amebiasis IBD 1. ). Other biological, mechanical, and pharmaceutical products are currently under development. This release contains forward-looking statements, including statements with respect to future products, services, markets and financial results. These statements involve risks and uncertainties that could cause actual results to differ materially. Risks include without limitation the Company's ability to penetrate new markets, the results of our accounting investigation when complete, the degree of market acceptance of new products, the outcome of the Company's patent litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. appeal, the complete commercial development of potential future products or the ability to obtain regulatory approval of products. Such approval is dependent upon a number of factors, such as results of trials, the discretion of regulatory officials, and potential changes in regulations. These statements are also contingent upon continued growth of the global poultry industry and economic viability of certain markets. Additional information on these risks and other factors, which could affect the Company's financial results, is included in the Company's Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. filed with the Securities and Exchange Commission (SEC) and other filings with the SEC. Embrex(R), Inovoject(R), Bursaplex(R), VNF(R) and Vaccine Saver(R) are registered trademarks of Embrex, Inc. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion